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doi:10.1Objective:Aortic valve disease is the most common acquired valvular heart disease in adults.With the increasing
elderly population, the proportion of patients with symptomatic aortic stenosis who are unsuitable for conven-
tional surgery is increasing. Transcatheter aortic valve implantation has rapidly gained credibility as a valuable
alternative to surgery to treat these patients; however, they often have severe iliac-femoral arteriopathy, which
renders the transfemoral approach unusable. We report our experience with the trans-subclavian approach for
transcatheter aortic valve implantation using the CoreValve (Medtronic CV Luxembourg S.a.r.l.) in 6 patients.
Methods: In May 2008 to September 2009, 6 patients (mean age of 82  5 years), with symptomatic aortic
stenosis and no reasonable surgical option because of excessive risk, were excluded from percutaneous femoral
CoreValve implantation because of iliac-femoral arteriopathy. These patients underwent transcatheter aortic valve
implantation via the axillary artery. Procedures were performed by a combined team of cardiologists, cardiac sur-
geons, and anesthetists in the catheterization laboratory. The CoreValve 18F delivery system was introduced via
the left subclavian artery in 6 patients, 1 with a patent left internal thoracic to left anterior descending artery graft.
Results: Procedural success was obtained in all patients, and the mean aortic gradient decreased 5 mm Hg or less
immediately after valve deployment. One patient required implantation of a permanent pacemaker. One patient
required a subclavian covered stent implantation to treat a postimplant artery dissection associated with difficult
surgical hemostasis. One patient was discharged in good condition but died of pneumonia 40 days after the pro-
cedure. All patients were asymptomatic on discharge, with good mid-term prosthesis performance.
Conclusions: Transcatheter aortic valve implantation via a surgical subclavian approach seems safe and feasible,
offering a new option to treat select, inoperable, and high-risk patients with severe aortic stenosis and peripheral
vasculopathy. (J Thorac Cardiovasc Surg 2010;140:911-5)E
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Aortic stenosis (AS) is the most frequent form of valvular
heart disease in adults in western countries,1 and aortic valve
replacement is the standard treatment for these patients.2
However, the mortality rate associated with aortic valve re-
placement increases substantially with age, the presence of
left ventricular dysfunction, ormultiple comorbidities.3 In re-
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The Journal of Thoracic and Cavalve implantation (TAVI) has rapidly gained credibility as
a valuable alternative to treat this group of patients who are
not considered for surgery because of significant comorbid-
ities.7,8 The 2 devices currently clinically available are the
Edwards-Sapien stainless-steel, balloon-expandable bovine
bioprosthesis (Edwards Lifesciences, Irvine, Calif) and the
CoreValve nitinol porcine self-expanding bioprosthesis
(Medtronic CV Luxembourg S.a.r.l.). The transfemoral ap-
proach is the preferred method for both devices, but with
a 24F or 18F introducer, respectively, the presence of small,
tortuous, heavily calcified femoral and iliac arteries contrain-
dicates this approach. To prevent vascular complications in
this group of patients, a transapical approach with the Ascen-
dra transapical catheter and the Edwards-Sapien valve
(Edwards Lifesciences) was preferred, but there is only ex-
perimental experience with this approach using the Core-
Valve. This approach seems demanding because it requires
direct left ventricle apex surgical exposure and a dedicated
operating room. We report our experience with retrograde
CoreValve implantation through the axillary artery in 6
high-risk surgical candidates with severe AS and heavily
calcified and atherosclerotic femoral and iliac arteries.rdiovascular Surgery c Volume 140, Number 4 911
Abbreviations and Acronyms
AS ¼ aortic stenosis
TAVI ¼ transcatheter aortic valve implantation
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SMATERIALS AND METHODS
FromMay 2008 to September 2009, 120 patients with severe, symptom-
atic AS and no reasonable surgical option because of excessive risk were
evaluated for TAVI. The patient screening protocol included transthoracic
echocardiography, complete left-sided heart catheterization, and coronary
angiography, with angiography of the iliac and femoral arteries, and chest
and aortic-iliac-femoral computed tomography scans. Acceptance for the
procedure required consensus by a team composed of a cardiac surgeon,
an interventional cardiologist, the referring cardiologist, and a cardiac anes-
thesiologist. All patients provide written informed consent, and all proce-
dures were approved by the local ethics committee. Forty-five patients
were eligible for CoreValve percutaneous femoral implantation, whereas
6 patients (5 male) with a mean age of 82 5 years were excluded because
of small size, calcification, iliac-femoral arteriopathy, or excessive tortuos-
ity. These patients underwent CoreValve implantation via the left axillary
artery. All patients underwent supra-aortic vessel angiography and com-
puted tomography to assess the left subclavian artery size, course, and cal-
cification (Figure E1). Two patients had previously undergone coronary
artery bypass grafting, and 1 patient had a patent left internal thoracic to
left anterior descending artery graft. Two patients had severe left ventricular
dysfunction, and 3 patients underwent a bridge procedure of balloon aortic
valvuloplasty. The patients’ characteristics are shown in Table 1.
The CoreValve ReValving System consists of 3 unique components:
a self-expanding support frame with a trileaflet porcine pericardial tissue
valve, an 18F catheter delivery system, and a disposable loading system,
as previously described.9-11
Operative Technique
The procedure was performed in the cardiac catheterization laboratory by
a team of interventional cardiologists, cardiac surgeons, and a cardiac anes-
thesiologist. All procedures were performed under general anesthesia. The
best femoral artery was accessed by a single wall puncture under fluoroscopic
and angiographic guidance to allow homodynamic monitoring and landmarkTABLE 1. Baseline patient characteristics at implant
Patient Gender
Age,
y Comorbidity
AoVArea
cm2
MAoG
mm Hg
P
D
1 M 78 Vasculopathy, porcelain aorta,
previous PCI
0.8 51
2 F 85 Vasculopathy,
thrombocythemia
0.8 51
3 M 74 Vasculopathy, AMI, bladder
neoplasm, IDDM, previous
CABG and PCI
1 52
4 M 86 Vasculopathy; IDDM, CRI,
previous PCI
0.9 47
5 M 85 Vasculopathy, stroke 0.9 62
6 M 85 Vasculopathy, IDDM, AMI,
previous CABG
1.1 47
Ao, Aorta; AMI, acute myocardial infarction; IDDM, insulin-dependent diabetes mellitus; C
Peak Ao D mm Hg, echo peak transvalvular aortic pressure gradient; LVEF, left ventricula
bypass grafting.
912 The Journal of Thoracic and Cardiovascular Surgaortic angiography through a 5F pigtail. A temporary pacing lead was ad-
vanced in the right ventricle through the right femoral vein in the patients
without a permanent pacemaker to treat possible post-TAVI atrioventricular
block. Heparinwas administered tomaintain an activated clotting time greater
than 250 seconds throughout the procedure. The axillary artery was surgically
isolated through a subclavicular incision of 3 to 5 cm just below the clavicle
(Figure E2). Arterial cannulation was performed using the Seldinger tech-
nique through a purse-string suture. The left axillary artery was usually
preferred because of the best angle of deployment. A 7F sheath was then in-
serted into the subclavian artery, and a 0.035 straight guidewire was placed in
the left ventricle using a left Amplatz catheter (Amplatz Cook, Inc, Blooming-
ton, Ind). A Cook 30-cmCheck-Flo Performer 18F introducer (WilliamCook
Europe, Bjaeverskov, Denmark) was inserted (Figure 1) over an Amplatz
super stiff guidewire, and the native aortic valve was predilated with a 22-
or 25-mmNucleus balloon (NuMED Inc, Hopkinton, NY) without rapid pac-
ing in all patients. The balloon design facilitates positive positioning while
holding the balloon in the correct location, and initial inflation will hold the
balloon in the desired position. A CoreValve prosthesis was then carefully
introduced and retrogradely implanted under angiographic and fluoroscopic
guidance over the stiff wire in the ascending aorta across the aortic valve
(Figures 2, E3, and E4) with immediate improvement of the hemodynamic
status in all patients. Immediately after CoreValve deployment, ascending
aorta angiography was performed to assess the patency of the coronary
arteries and coronary grafts, and the presence and location of the eventual par-
avalvular leak (Figure 3). After the procedure, heparin was neutralized by
protamine, and the subclavian artery was restored by direct suture.
Statistical Analysis
Incidence rates of events are reported by giving the number of patients
experiencing the event followed by the corresponding percentage. Contin-
uous data are reported by giving the mean  standard deviation or median
and the range of values observed.RESULTS
According to definitions by Piazza and colleagues,12
procedural success was defined by the combination of 3 dif-
ferent end points: adequate technical placement, normal bio-
prosthesis performance, and operative outcome. Adequate
technical placement was the correct positioning of theeak Ao
mm Hg LVEF%
EuroSCORE Society of Thoracic Surgeons
Additive Logistic Mortality Morbidity
90 69 8 10 6.3% 28.9%
93 67 11 20 8.7% 29.9%
81 58 12 27 11% 41.9%
80 30 15 53 14.6% 42.7%
104 49 13 39 5.2% 30%
82 26 16 59 13.7% 45.5%
RI, chronic renal insufficiency; AoV, aortic valve area; MAoG, mean aortic gradient;
r ejection fraction; PCI, percutaneous coronary intervention; CABG, coronary artery
ery c October 2010
FIGURE 1. After subclavian exposure, the 18F introducer is inserted over
an Amplatz (Amplatz Cook, Inc, Bloomington, Ind) super stiff guidewire.
FIGURE 3. Immediately after CoreValve deployment, ascending aorta an-
giography was performed to assess the correct positioning of the device,
periprosthesis regurgitation, and patency of the coronary arteries.
Bruschi et al Evolving Technology/Basic ScienceCoreValve in the aortic root. Good valve performance was
evidenced by a reduction in mean transaortic gradient to
less than 20 mm Hg and aortic regurgitation grade of 2 or
less, as evaluated by aortic angiogram or echocardiogram.
Operative outcome was represented by any event occurring
during the procedure and within the subsequent 24 hours.
Any events occurring within 30 days from the procedure
were considered procedure related.12 Events collected
were death, neurologic event, myocardial infarction, ventric-
ular perforation, cardiac tamponade, aortic dissection, vas-
cular access complication, infections, and contrast-inducedFIGURE 2. CoreValve (Medtronic CV Luxembourg S.a.r.l.) delivery
catheter and prosthesis are advanced in place. Notice the short distance
from the subclavian access to the aortic annulus requiring weaker forces
of tension and torsion.
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subclavian artery in 6 patients. In patient 6, the procedure
was performed through the left subclavian artery with a pat-
ent left internal thoracic artery graft on the descending ante-
rior coronary artery. Aortic valvuloplasty was performed to
predilate the native valve in all patients. The mean duration
of the procedure was 147  63 minutes (range, 105–270
minutes), with a mean fluoroscopy time of 28  14 minutes
and a mean contrast medium amount of 186  84 mL. Pro-
cedural success was obtained in all cases. Mean aortic gradi-
ent decreased 5 mm Hg or less immediately after valve
deployment in all patients. Two patients had grade 1 to 2 aor-
tic insufficiency (Table 2). In patient 6, post-deployment
valve dilation was performed to improve CoreValve strut
expansion to reduce paraprosthetic leak. After removal of
the 18F sheath and surgical closure of the axillary artery,
the radial pulse disappeared in patient 4. The surgeon had
also some difficulty in obtaining an adequate hemostasis at
the puncture site. An immediate angiography at this level re-
vealed a long dissection with a flow-limiting stenosis at the
puncture site, which was treated with Gore Viabahn 8350
mm (WL Gore and Associates Inc, Flagstaff, Ariz) covered
polytetrafluoroethylene stent implantation. At 8 months
follow-up, the left radial pulse is normal in this patient. All
patients were extubated after the end of the procedure in
the catheterization laboratory. Post-implant complete atrio-
ventricular block developed in patient 5, who required per-
manent pacemaker implantation via the right subclavian
vein. All patients were asymptomatic on discharge withrdiovascular Surgery c Volume 140, Number 4 913
TABLE 2. Procedural details and complications
Patient Valve size (mm) Implant time (min) DAP Gycm2 P-t-P Ao gradient (mm Hg) Aortic insufficiency Complications
1 29 110 213 4 1þ —
2 26 105 50 5 1þ —
3 29 115 105 5 1þ —
4 29 270 240 2 1þ Subclavian stent
5 29 160 313 4 1–2þ PM implant
6 29 125 212 4 1–2þ ARF
DAP, Radiation dose/area product; P-t-P Ao, hemodynamic peak-to-peak trans-aortic gradient; PM, pacemaker; ARF, acute renal failure (creatinine clearance<30 mL/min).
Evolving Technology/Basic Science Bruschi et al
E
T
/B
Sgood prosthesis function as assessed by echocardiography
after a mean hospitalization of 13 days (range 7–22 days)
with a dual antiplatelet regimen of aspirin 100 mg and clopi-
dogrel 75 mg daily for 3 months, after which 100 mg of
aspirin daily was prescribed indefinitely. Regular clinical
and echocardiography follow-up were performed after
discharge in all patients at 1, 3, 6, and 12 months and if clin-
ically necessary. At discharge the average of mean trans-
valvular aortic pressure gradient was 9  4 mm Hg.
During follow-up, all patients experienced functional class
improvement after CoreValve implant at a mean time of
341  166 days (range 41–470 days). Five patients are
asymptomatic and have returned to normal life activities,
limited only by their previous medical conditions. One
patient was rehospitalized after discharge and died of pneu-
monia 41 days after the procedure. Two patients required
femoral artery percutaneous transluminal angioplasty, and
1 patient underwent iliac-femoral bypass surgery. One pa-
tient experienced lower-extremity cholesterinic embolism
that was successfully medically treated (Table E1). Echocar-
diographic controls, at 1 year, showed stable and good pros-
thesis performance, with an average mean transvalvular
aortic pressure gradient of 9 4 mm Hg, and mild aortic in-
sufficiency caused by trivial paravalvular leak in 3 patients
(Table E2).
DISCUSSION
TAVI has emerged as an alternative therapy to treat
patients with symptomatic AS who are not considered for
surgery because of high-risk surgical features.7,8 In the last
5 years, approximately 10,000 patients have been treated
worldwide for severe AS using a TAVI technique.13 Several
technical approaches were applied, including antegrade
approaches via the femoral vein and transseptal puncture,
retrograde approaches via the femoral arteries, and the trans-
apical approach via a minithoracotomy.4-6 The choice for the
best approach depends on a patient’s morbidity and
tortuosity; the presence of excessive femoral, iliac, or aortic
atherosclerosis; and the size and type of the device used.
The antegrade transvenous approach14 theoretically
seems more suitable to introduce the large delivery system,
reducing the risk of vascular complications. However, trans-
septal puncture makes this approach challenging, and pas-
sage of large-diameter catheters through the mitral valve914 The Journal of Thoracic and Cardiovascular Surgmay damage the mitral valve apparatus; thus, this approach
has been abandoned.5
After reducing the size of the delivery catheters, the pre-
ferred access site for TAVI is the retrograde approach via
the femoral arteries; however, actual selection criteria of pa-
tients of advanced agewith porcelain aorta or previous cardiac
surgery, select a cohort of patients at high risk for peripheral
artery disease, and non-permissive retrograde transfemoral ar-
terial approach. This conditionmay be overcomeby a transap-
ical approach widely and successfully performed using the
Edwards-Sapien valve.6,15 This approach allows the
introduction of delivery systems directly through the apex of
the left ventricle without sheath diameter limitation. This
approach is more invasive and requires an anterolateral
minithoracotomy in a hybrid operating room.15 Moreover,
transapical valve implantation has some technical limitations,
as in the case of severe septal hypertrophy in combinationwith
the angled position of the left ventricular outflow tract in rela-
tion to the aortic root and unique potential complications, such
as significant incidence of perivalvular leak,myocardial perfo-
ration, andmitral or aortic trauma that may occur frommisdir-
ected stiff catheters.16,17 In this scenario, as recently reported
by other authors, a trans-subclavian retrograde approach could
represent an intriguing alternative for TAVI in high-risk pa-
tients with associated severe iliac-femoral arteriopathy.18-20
The axillary artery is easily accessible after surgical cut-
down, and its size allows the introduction of 18F sheaths.
The CoreValve Extended Evaluation Registry has reported
data for approximately 74 patients inwhom subclavian access
was used with 100% procedural success.21 Our experience
confirms the possibility of performing CoreValve implanta-
tion through the left subclavian artery in a patient with a patent
internal thoracic graft to the left anterior descending artery. In
this case, as suggested by Fraccaro and colleagues,19 it may be
safer to completely introduce the sheath only to implant the
valve and then slightly retrieve the sheath to minimize
the risk of thoracic flow obstruction. Some operators have ex-
periencewith right subclavian access.18 This access is feasible
even if correct positioning of the valve is made difficult by
the fact that the stiff wire used to deliver the valve is pushed
against the left aspect of the aorta. In case of aortic annuli
with a significant inclination on the sagittal plane (>30
degrees; Jean-Claude Laborde, personal communication,
March 2009), correct CoreValve implantation is difficultery c October 2010
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annulus. In the trans-subclavian approach, the proximity be-
tween the aortic annulus and the sheath of the valve provides
moredirect access to the implantation site, easiermanipulation
of the device, and correct positioning of theCoreValve (partic-
ularly during the stepwise retraction of the outer sheath that al-
lows deployment of the self-expanding prosthesis) than the
transfemoral approach, because no bending of the aorta and
pelvic arteries hinders the control of the device.
The axillary approach also has the advantage of overcom-
ing challenging aorto-ileo-femoral vascular disease, without
the invasiveness of the transapical technique, and avoids the
risk of dislodging atherosclerotic plaque during valve
passage through the aorta, which may cause particulate em-
bolization and subsequent stroke. None of our patients had
neurologic events. As with the transapical approach, proce-
dural times are longer than in percutaneous transfemoral im-
plantation.15,19 In our experience, the subclavian procedural
length (mean implant time 147 minutes) was longer than the
percutaneous transfemoral implantation (mean implant time
111 minutes), but was comparable to the time necessary for
an implant requiring femoral artery surgical cut-down, al-
though the trans-subclavian approach enables a more rapid
mobilization of the patients. Except for subclavian dissec-
tion in 1 patient, no other vascular problem occurred in
our series; no other patients experienced bleeding or difficult
surgical hemostasis despite double-antiplatelet therapy.
No surgical wound infections occurred, and all patients
were discharged in good health conditions and stable hemo-
dynamic compensation 2 weeks after valve implant. During
follow-up, all patients had improved New York Heart Asso-
ciation functional class and functional capacity, and echo-
cardiograms showed good valve performance at 16 months.
In our series, 2 patients required permanent pacemaker
implantation after TAVI. Permanent pacemaker requirement
after CoreValve implantation is reported to be 33% in-
hospital and 40% within 1 year. The cause is that the native
aortic valve remains in situ and is compressed by the
CoreValve stent frame against the surrounding structures ad-
jacent to the left ventricular outflow and aortic annulus, in-
cluding the atrioventricular node and its left bundle branch.22CONCLUSIONS
Our experience, characterized by a multidisciplinary con-
tribution necessary to offer the safest conditions and care for
patients, confirms the safety and feasibility of the subclavian
approach with the immediate hemodynamic success of the
treatment.The Journal of Thoracic and CaReferences
1. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormal-
ities in the elderly: an echocardiographic study of a random population sample.
J Am Coll Cardiol. 1993;2:1220-5.
2. Bonow RO, Carabello B, Chatterjee K, et al. ACC/AHA 2006 guidelines for the
management of valvular heart disease. J Am Coll Cardiol. 2006;48:e1-148.
3. Charlson E, Legedza AT, Hamel MB. Decision-making and outcomes in severe
symptomatic aortic stenosis. J Heart Valve Dis. 2006;15:312-21.
4. Cribier A, Eltchaninoff H, Bash A, et al. Percutaneous transcatheter implantation
of an aortic valve prosthesis for calcific aortic stenosis: first human case descrip-
tion. Circulation. 2002;106:3006-8.
5. Webb JG, Chandavimol M, Thompson C, et al. Percutaneous aortic valve implan-
tation retrograde from the femoral artery. Circulation. 2006;113:842-50.
6. Ye J, Cheung A, Lichtenstein SV, et al. Transapical aortic valve implantation in
humans. J Thorac Cardiovasc Surg. 2006;131:1194-6.
7. Grube E, Buellesfeld L, Mueller R, et al. Progress and current status of percuta-
neous aortic valve replacement: results of three device generations of the Core-
Valve Revalving System. Circ Cardiovasc Intervent. 2008;1:167-75.
8. Webb JG, Altwegg L, Boone RH, et al. Transcatheter aortic valve implantation—
impact on clinical and valve-related outcomes. Circulation. 2009;119:3009-16.
9. Grube E, Laborde JC, Gerckens U, et al. Percutaneous implantation of the Core-
Valve self-expanding valve prosthesis in high-risk patients with aortic valve
disease: The Siegburg First-in-Man Study. Circulation. 2006;114:1616-24.
10. Leon MB, Kodali S, Williams M, et al. Transcatheter aortic valve replacement
in patients with critical aortic stenosis: rationale, device descriptions, early clin-
ical experiences, and perspectives. Semin Thorac Cardiovasc Surg. 2006;18:
165-74.
11. Marcheix B, Lamarche Y, Berry C, et al. Surgical aspects of endovascular retro-
grade implantation of the aortic CoreValve bioprosthesis in high-risk older
patients with severe symptomatic aortic stenosis. J Thorac Cardiovasc Surg.
2007;134:1150-6.
12. Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day outcomes following
transcatheter aortic valve implantation using the third generation (18 Fr)
CoreValve ReValving System: results from the multicentre, expanded evaluation
registry 1-year following CE mark approval. EuroIntervention. 2008;4:242-9.
13. PC Block: TheNext Generation of Transcatheter Aortic Valve Devices. Cardiac In-
terventions Today. 2009: September 79-82. Available at: http://www.bmctoday.net/
citoday/2009/09. Accessed September 20, 2009.
14. Cribier A, Eltchaninoff H, Tron C, et al. Early experience with percutaneous trans-
catheter implantation of heart valve prosthesis for the treatment of end-stage inop-
erable patients with calcific aortic stenosis. J Am Coll Cardiol. 2004;43:698-703.
15. Walther T, Simon P, Dewey T, et al. Transapical minimally invasive aortic valve
implantation multicenter experience. Circulation. 2007;116(11 Suppl):I240-5.
16. Lichtenstein SV, Cheung A, Ye J, et al. Transapical transcatheter aortic valve im-
plantation in humans: initial clinical experience. Circulation. 2006;114:591-6.
17. Ye J, Cheung A, Lichtenstein SV, et al. Transapical transcatheter aortic valve im-
plantation: 1-year outcome in 26 patients. J Thorac Cardiovasc Surg. 2009;137:
167-73.
18. Ruge H, Lange R, Bleiziffer S, et al. First successful aortic valve implantation with
the CoreValve ReValving System via right subclavian artery access: a case report.
Heart Surg Forum. 2008;11:E323-4.
19. Fraccaro C, Napodano M, Tarantini G, et al. Expanding the eligibility for trans-
catheter aortic valve implantation: the trans-subclavian retrograde approach using
the III Generation CoreValve Revalving System. J Am Coll Cardiol Interv. 2009;
2:828-33.
20. Jilaihawi H, Spyt T, Chin D, Logtens E, Laborde JC, Kovac J. Percutaneous aortic
valve replacement in patients with challenging aortoiliofemoral access. Catheter
Cardiovasc Interv. 2008;72:885-90.
21. Medtronic’s CoreValve shows subclavian access success in patients contraindicated
for femoral approach [press release]. Available at: http://www.medicalnewstoday.
com/articles/150929.php. Accessed July 23, 2009.
22. Jilaihawi H, Chin D, Vasa-Nicotera M, et al. Predictors for permanent pacemaker
requirement after transcatheter aortic valve implantation with the CoreValve bio-
prosthesis. Am Heart J. 2009;157:860-6.rdiovascular Surgery c Volume 140, Number 4 915
FIGURE E1. Supra -aortic vessel angiography to assess left subclavian
artery size, course, and calcification.
FIGURE E2. Subclavian exposure after incision of cutaneous and subcu-
taneous tissue.
FIGURE E3. The CoreValve revalving system 18F introducer was care-
fully advanced to the ascending aorta.
FIGUREE4. After careful checking of the CoreValve’s position, the valve
was released.
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TABLE E1. Patients’ clinical follow-up
Patient
NYHA
class Events Outcome
Follow-up
(mo)
1 I AF, PM Alive 16
2 I PTA and iliac-femoral
bypass of femoral artery
Alive 15
3 I PTA of femoral artery Alive 15
4 II HF episode Alive 12
5 NA Pneumonia Death 1
6 I Cholesterinic embolism Alive 9
NYHA, New York Heart Association; AF, atrial fibrillation; PM, pacemaker; PTA,
percutaneous transluminal angioplasty; HF, heart failure.
TABLE E2. Patients’ echocardiographic follow-up
1 mo 6 mo 1 y
Patient MAoG mm Hg LVEF% AoI MAoG mm Hg LVEF% AoI MAoG mm Hg LVEF% AoI
1 10 63 1þ 6 50 1þ 8 50 1þ
2 6 65 0 6 51 0 13 54 0
3 9 58 1þ 11 63 1þ 9 64 1þ
4 4 35 1þ 5 37 1þ 4 38 1þ
5 16 50 2 — — — — — —
6 11 49 1–2þ 6 53 — — — —
MAoG, Mean aortic gradient; AoI, aortic insufficiency; LVEF, left ventricular ejection fraction.
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